Levodopa/Carbidopa(WD Pharmaceutical)

左旋多巴/卡比多巴（汉都医药）

Report date: 2025/07/09 16:33:04

Base Information

Drug NameLevodopa/Carbidopa(WD Pharmaceutical)
Drug Alias Name卡左双多巴片/左旋多巴口腔控释片WD-1804
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDOPA decarboxylase inhibitorsDopamine receptors agonists
TargetsAromatic-L-amino-acid decarboxylaseDopamine receptors
Therapy Area/IndicationsParkinsonian Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai WD Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai WD Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsParkinsonian Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A